| Dr Hilary Yegen Robbins, MD | |
|
622 W 168th St, Department Of Pulmonary And Critical Care, Ph-8, New York, NY 10032-3720 | |
| (212) 305-2323 | |
| Not Available |
| Full Name | Dr Hilary Yegen Robbins |
|---|---|
| Gender | Female |
| Speciality | Pulmonary Disease |
| Experience | 21 Years |
| Location | 622 W 168th St, New York, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013175371 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 237429 (New York) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | 237429 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Hudson Valley Hospital Center | Cortlandt manor, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trustees Of Columbia University In The City Of New York | 8527972546 | 1895 |
News Archive
Medical technology pioneer Forest Devices, Inc. today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive strokes in emergency departments in the American Heart Association Journal, STROKE.
The record high temperatures that have dominated most of the summer are continuing to make outdoor activities more dangerous. Despite the extreme heat and humidity many people are exercising outside, knowing winter is just around the corner.
After snuff use, heart rate increased by about 15 beats per minute (25 percent), systolic blood pressure went up by 12 mmHg (10 percent), and measurements of adrenalin in the bloodstream increased by more than 50 percent.
Each year, thousands of people are treated in emergency departments across the United States for heart attacks, broken bones and other injuries related to snow shoveling.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 2 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437176047 PECOS PAC ID: 6002715794 Enrollment ID: O20031231000637 |
News Archive
Medical technology pioneer Forest Devices, Inc. today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive strokes in emergency departments in the American Heart Association Journal, STROKE.
The record high temperatures that have dominated most of the summer are continuing to make outdoor activities more dangerous. Despite the extreme heat and humidity many people are exercising outside, knowing winter is just around the corner.
After snuff use, heart rate increased by about 15 beats per minute (25 percent), systolic blood pressure went up by 12 mmHg (10 percent), and measurements of adrenalin in the bloodstream increased by more than 50 percent.
Each year, thousands of people are treated in emergency departments across the United States for heart attacks, broken bones and other injuries related to snow shoveling.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 2 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982993184 PECOS PAC ID: 8527972546 Enrollment ID: O20040407001360 |
News Archive
Medical technology pioneer Forest Devices, Inc. today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive strokes in emergency departments in the American Heart Association Journal, STROKE.
The record high temperatures that have dominated most of the summer are continuing to make outdoor activities more dangerous. Despite the extreme heat and humidity many people are exercising outside, knowing winter is just around the corner.
After snuff use, heart rate increased by about 15 beats per minute (25 percent), systolic blood pressure went up by 12 mmHg (10 percent), and measurements of adrenalin in the bloodstream increased by more than 50 percent.
Each year, thousands of people are treated in emergency departments across the United States for heart attacks, broken bones and other injuries related to snow shoveling.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 2 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
Medical technology pioneer Forest Devices, Inc. today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive strokes in emergency departments in the American Heart Association Journal, STROKE.
The record high temperatures that have dominated most of the summer are continuing to make outdoor activities more dangerous. Despite the extreme heat and humidity many people are exercising outside, knowing winter is just around the corner.
After snuff use, heart rate increased by about 15 beats per minute (25 percent), systolic blood pressure went up by 12 mmHg (10 percent), and measurements of adrenalin in the bloodstream increased by more than 50 percent.
Each year, thousands of people are treated in emergency departments across the United States for heart attacks, broken bones and other injuries related to snow shoveling.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hilary Yegen Robbins, MD 630 W 168th St, Box 4, New York, NY 10032-3725 Ph: (212) 342-5155 | Dr Hilary Yegen Robbins, MD 622 W 168th St, Department Of Pulmonary And Critical Care, Ph-8, New York, NY 10032-3720 Ph: (212) 305-2323 |
News Archive
Medical technology pioneer Forest Devices, Inc. today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive strokes in emergency departments in the American Heart Association Journal, STROKE.
The record high temperatures that have dominated most of the summer are continuing to make outdoor activities more dangerous. Despite the extreme heat and humidity many people are exercising outside, knowing winter is just around the corner.
After snuff use, heart rate increased by about 15 beats per minute (25 percent), systolic blood pressure went up by 12 mmHg (10 percent), and measurements of adrenalin in the bloodstream increased by more than 50 percent.
Each year, thousands of people are treated in emergency departments across the United States for heart attacks, broken bones and other injuries related to snow shoveling.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.
› Verified 2 days ago
Dr. Ravishankar Ramaswamy, MD, MS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |